Iomai Corporation strives to discover and develop vaccines and immune system stimulants which could be administered through a novel, needle-free technology called ‘Transcutaneous Immunization (TCI)’.It tried to establish that a single dose of pandemic influenza vaccine may meet the protection level. FDA recommends a pandemic vaccine which can achieve immune response levels considered protective in 70 percent or more of vaccine recipients.
It has recently announced its positive interim results of the trial among 500 subjects with the use of its immunostimulant adjuvant patch with an injected vaccine for H5N1 influenza.
The trial demonstrated a significant influence of lomai patch when it was used with a single dose of the 45-microgram H5N1 vaccine. It proved that this combination was sufficient to provide an immune response considered protective in 73 percent of those tested. This could be counted as a statistically significant improvement over those who received the H5N1 Influenza vaccine alone.
